Galactosylated α,β-poly[(2-hydroxyethyl)-L-aspartamide]-bound doxorubicin: Improved antitumor activity against hepatocellular carcinoma with reduced hepatotoxicity

Anti-Cancer Drugs

Volumn 22, Issue 2, 2011, Pages 136-147

  Cheng, Xiaoyun ^a,b   Gao, Fengbo ^a   Xiang, Jiawei ^a   Jiang, Xiqun ^b,d   Chen, Jiangning ^a,c   Zhang, Junfeng ^a,c,d  

^a School of Life Sciences   (China)

^b Key Laboratory for Bio Nanotechnology and Molecular Engineering of Hunan Province   (China)

^c Jiangsu Provincial Diabetes Center   (China)

^d NANJING UNIVERSITY   (China)

Author keywords

, poly (2 hydroxyethyl) L aspartamide ; doxorubicin; galactosyl; hepatocellular carcinoma; hepatotoxicity

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; DRUG CARRIER; GALACTOSE; GALACTOSYL ALPHA,BETA POLY(2 HYDROXYETHYL)ASPARTAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONJUGATE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG MEGADOSE; LIVER CELL CARCINOMA; LIVER TOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG-INDUCED LIVER INJURY; FEMALE; GALACTOSE; HEART DISEASES; HELA CELLS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED ICR; PEPTIDES; TOXICITY TESTS;

EID: 78650767381     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283406e85     Document Type: Article

References (33)

1. Olweny CL, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalwazi SK, Cohen H. Treatment of hepatocellular carcinoma with adriamycin. Cancer 1975; 36:1250-1257.
2. Leung TWT, Johnson PJ. Systemic therapy for hepatocellular carcinoma. Semin Oncol 2001; 28:514-520.
3. Huang CC,Wu MC, Xu GW, Li DZ, Cheng H, Tu ZX, et al. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 1992; 84:262-264.
4. Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: A review. Eur J Cancer 2004; 40:1474-1484.
5. Treré D, Fiume L, De Giorgi LB, Di Stefano G, Migaldi M, Derenzini M. The asialoglycoprotein receptor in human hepatocellular carcinomas: Its expression on proliferating cells. Br J Cancer 1999; 81:404-408.
6. Duncan R. Designing polymer conjugates as lysosomotropic nanomedicines. Biochem Soc Trans 2007; 35:56-60.
7. Di Stefano G, Lanza M, Kratz F, Merina L, Fiume L. A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: Synthesis, characterization and preliminary biological properties of the conjugate. Eur J Pharm Sci 2004; 23:393-397.
8. Matsuda I, Konno H, Tanaka T, Nakamura S. Antimetastatic effect of hepatotropic liposomal adriamycin on human metastatic liver tumors. Surg Today 2001; 31:414-420.
9. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, et al. Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002; 20:1668-1676.
10. Hopewell JW, Duncan R, Wilding D, Chakrabarti K. Preclinical evaluation of the cardiotoxicity of PK2: A novel HPMA copolymer-doxorubicin- galactosamine conjugate antitumour agent. Hum Exp Toxicol 2001; 20:461-470.
11. Fiume L, Bolondi L, Busi C, Chieco P, Kratz F, Lanza M, et al. Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine. J Hepatol 2005; 43:645-652.
12. O'Hare KB, Hume IC, Carlett SL, Duncan R. Evaluation of anticancer agents coupled to N-(2-hydroxypropyl)-methacrylamide copolymers. Effect of galactose incorporation on interaction with hepatoma in vitro. Hepatology 1989; 10:207-214.
13. Seymour LW, Ulbrich K, Strohalm J, Duncan R. Pharmacokinetics of a polymeric drug carrier targeted to the hepatocyte galactose receptor. Br J Cancer 1991; 63:859-866.
14. Di Stefano G, Derenzini M, Kratz F, Lanza M, Fiume L. Liver-targeted doxorubicin: Effects on rat regenerating hepatocytes. Liver Int 2004; 24:246-252.
15. Xu ZH, Chen LL, Gu WW, Gao Y, Lin LP, Zhang ZW, et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 2009; 30:226-232.
16. Injac R, Perse M, Cerne M, Potocnik N, Radic N, Govedarica B, et al. Protective effects of fullerenol C60(OH)24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer. Biomaterials 2009; 30:1184-1196.
17. Raschi E, Vasina V, Ursino MG, Boriani G, Martoni A, De Ponti F. Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. Pharmacol Ther 2010; 125:196-218.
18. Cheng XY, Xue WH, Diao HJ, Xia SH, Zuo LS, He AJ, et al. Antitumor activity and toxicological properties of doxorubicin conjugated to a,b-poly[(2-hydroxyethyl)-L-aspartamide] administrated intraperitoneally in mice. Anticancer Drugs 2010; 21:362-371.
19. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): The beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003; 22:177-203.
20. Monsigny M, Petit C, Roche AC. Colorimetric determination of neutral sugars by a resorcinol sulfuric acid micromethod. Anal Biochem 1988; 175:525-530.
21. Frauer D, Frigerio E, Pianezzola E, Strolin Benedetti M, Cassidy J, Vasey P. A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl) methacylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone, in human plasma and urine by reversed-phase HPLC with fluorimetric detection. J Pharm Biomed Anal 1995; 13:625-633.
22. Seymour LW, Ulbrich K, Strohalm J, Kopecek H, Duncan R. The pharmacokinetics of polymer-bound adriamycin. Biochem Pharmacol 1990; 39:1125-1131.
23. Mürdtera TE, Sperkera B, Bossletb K, Fritza P, Kroemer HK. Simultaneous high-performance liquid chromatographic determination of a glucuronyl prodrug of doxorubicin, doxorubicin and its metabolites in human lung tissue. J Chromatogr B 1998; 709:289-295.
24. Kim TH, Park IK, Nah JW, Choi YJ, Cho CS. Galactosylated chitosan/DNA nanoparticles prepared using water-soluble chitosan as a gene carrier. Biomaterials 2004; 25:3783-3792.
25. Chun CJ, Lee SM, Kim CW, Hong KY, Kim SY, Yang HK, et al. Doxorubicinpolyphosphazene conjugate hydrogels for locally controlled delivery of cancer therapeutics. Biomaterials 2009; 30:4752-4762.
26. Virgolini I, Müller C, Klepetko W, Angelberger P, Bergmann H, O'Grady J, et al. Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand. Br J Cancer 1990; 61:937-941.
27. Tomlinson R, Heller J, Brocchini S, Duncan R. Polyacetal-doxorubicin conjugates designed for pH-dependent degradation. Bioconjug Chem 2003; 14:1096-1106.
28. Hovorka O, Ştastný M, Etrych T, Şubr V, Strohalmb J, Ulbrich K, et al. Differences in the intracellular fate of free and polymer-bound doxorubicin. J Control Release 2002; 80:101-117.
29. Zhang C, Qu GW, Sun YJ,Wu XL, Yao Z, Guo QL, et al. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. Biomaterials 2008; 29:1233-1241.
30. Fiume L, Baglioni M, Bolondi L, Farina C, Di Stefano G. Doxorubicin coupled to lactosaminated human albumin: A hepatocellular carcinoma targeted drug. Drug Discov Today 2008; 13:1002-1009.
31. King HD, Staab AJ, Pham-Kaplita K, Yurgaitis D, Firestone RA, Laschb SJ, Trailb PA. BR96 conjugates of highly potent anthracyclines. Bioorg Med Chem Lett 2003; 13:2119-2122.
32. Calderón M, Warnecke A, Gräser R, Haag R, Kratz F. Development of enzymatically cleavable doxorubicin conjugates with polyglycerol. J Control Release 2008; 132:e54-e55.
33. Cui JX, Li CL, Guo WM, Li YH, Wang CX, Zhang L. Direct comparison of two pegylated liposomal doxorubicin formulations: Is AUC predictive for toxicity and efficacy? J Control Release 2007; 118:204-215.